XORTX Therapeutics (XRTX) Free Cash Flow (2022 - 2023)

XORTX Therapeutics (XRTX) posted Free Cash Flow of $1637.0 for Q2 2023, down 38.76% on a QoQ basis from $2673.0 in Q1 2023.

XORTX Therapeutics (XRTX) Free Cash Flow (2022 - 2023) Analysis & Trends

XORTX Therapeutics' Free Cash Flow history runs 2 years deep, the most recent figure standing at $1637.0 for Q2 2023.

Quarterly Free Cash Flow changed N/A year-over-year to $1637.0 in Q2 2023, while the trailing twelve-month figure through Mar 2024 was $1637.0 (up 100.01% YoY) and the FY2025 annual result came in at -$2.8 million, up 24.74% from the prior year.
Free Cash Flow was $1637.0 for Q2 2023 at XORTX Therapeutics, down from $2673.0 in the prior quarter.
Across five years, Free Cash Flow topped out at $951980.6 in Q3 2022 and bottomed at -$13.9 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Free Cash Flow (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-19.58 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	158.09 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-1.53 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	1.29 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	848.30 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-354.95 Mn
10	XORTX Therapeutics	20.40 Mn	20.40 Mn	-	-

Download Data